Edition:
United States

Synthetic Biologics Inc (SYN.A)

SYN.A on American Stock Exchange

0.75USD
24 Feb 2017
Change (% chg)

$0.01 (+1.17%)
Prev Close
$0.74
Open
$0.77
Day's High
$0.77
Day's Low
$0.73
Volume
44,543
Avg. Vol
112,602
52-wk High
$2.73
52-wk Low
$0.73

SYN.A

Chart for SYN.A

About

Synthetic Biologics, Inc. is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company's lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the... (more)

Overall

Beta: 0.98
Market Cap(Mil.): $87.56
Shares Outstanding(Mil.): 116.65
Dividend: --
Yield (%): --

Financials

  SYN.A Industry Sector
P/E (TTM): -- 44.08 29.63
EPS (TTM): -0.39 -- --
ROI: -335.98 -3.35 12.96
ROE: -335.28 5.80 14.11

BRIEF-Synthetic Biologics says confirms key features of Phase 2B/3 trial of SYN-010

* Synthetic Biologics confirms key features of pivotal Phase 2b/3 trial of SYN-010 pursuant to consultations with FDA

Jan 18 2017

Synthetic Biologics' C. difficile mid-stage study meets main goal

Synthetic Biologics Inc said its experimental treatment designed to reduce antibiotic-resistant "superbug" infections - notably life-threatening C. difficile - outperformed a placebo in a trial.

Jan 05 2017

BRIEF-Sabby Management reports 5.14 pct passive stake in Synthetic Biologics

* Sabby Management LLC reports 5.14 percent passive stake in Synthetic Biologics Inc as of November 15 - sec filing Source text : http://bit.ly/2f8su9r Further company coverage:

Nov 17 2016

BRIEF-Synthetic Biologics announces pricing of public offering of common stock

* Pricing of offering of 25 million shares of its common stock and warrants to purchase 50 million shares of common stock at $1.00/share

Nov 15 2016

BRIEF-Synthetic Biologics says commences offering of stock and warrants

* Synthetic Biologics - using net proceeds from offering primarily to provide necessary funding for continued clinical development of SYN-010

Nov 14 2016

BRIEF-Synthetic Biologics posts quarterly loss of 9 cents/share

* Synthetic biologics reports third quarter 2016 operational highlights and financial results Source text for Eikon: Further company coverage:

Nov 01 2016

BRIEF-Synthetic Biologics awarded research contract from Centers for Disease Control and Prevention (CDC)

* Synthetic Biologics awarded research contract from Centers For Disease Control And Prevention (CDC) for microbiome assessment and intervention to address antibiotic resistance

Oct 06 2016

BRIEF-Synthetic Biologics announces completion of enrollment for Phase 2b

* Announces completion of enrollment for Phase 2b Proof-Of-Concept clinical trial for SYN-004 (ribaxamase)

Sep 20 2016

More From Around the Web

Earnings vs. Estimates